Physician profile
Robert K Bailey
NPI 1568695039
$7,615.41
in general payments reported to CMS, 2019-2025
33 companies · $1,509 in 2025
The $1,509 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $515 · 2020: $856 · 2021: $1,428 · 2022: $1,116 · 2023: $735 · 2024: $1,456 · 2025: $1,509.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,700.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,699.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,934.11 | 2020-2025 | Skyrizi, Rinvoq, Linzess |
| Stryker Corporation | $1,299.13 | 2019-2023 | Lite Plate System |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $973.37 | 2019-2025 | Xifaxan, Trulance, Plenvu |
| Takeda Pharmaceuticals U.S.A., INC. | $621.51 | 2019-2025 | Entyvio, Eohilia, Gattex |
| Janssen Biotech, INC. | $538.58 | 2019-2025 | Tremfya, Stelara, Remicade |
| Ardelyx, INC. | $245.92 | 2022-2025 | Ibsrela |
| Ipsen Biopharmaceuticals, INC | $208.43 | 2024-2025 | Iqirvo, Bylvay |
| Actuated Medical, INC. | $200.00 | 2022 | |
| Lilly USA, LLC | $141.72 | 2024-2025 | Omvoh |
| Intercept Pharmaceuticals, INC. | $133.22 | 2021-2025 | |
| Daiichi Sankyo INC. | $112.17 | 2019-2023 | Injectafer |
| Pfizer INC. | $107.64 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $93.22 | 2024-2025 | Dupixent |
| Braintree Laboratories, INC. | $91.77 | 2020-2024 | Suflave |
| Amgen INC. | $86.76 | 2020-2021 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $83.50 | 2022-2024 | |
| Madrigal Pharmaceuticals | $81.51 | 2024-2025 | Resmetirom, Rezdiffra |
| Celgene Corporation | $81.16 | 2021-2023 | Zeposia |
| Phathom Pharmaceuticals, INC. | $72.37 | 2025 | Voquezna |
| Ferring Pharmaceuticals INC. | $70.46 | 2020-2025 | Rebyota |
| Biofire Diagnostics, LLC | $59.68 | 2020 | |
| Merck Sharp & Dohme LLC | $59.11 | 2023-2024 | Dificid, Zinplava |
| Exeltis, USA INC. | $55.67 | 2019-2020 | |
| Celltrion USA INC. | $51.23 | 2025 | Vegzelma |
| Qol Medical, LLC | $36.29 | 2022 | |
| Boston Scientific Corporation | $33.76 | 2020 | |
| Ironwood Pharmaceuticals, INC | $30.59 | 2022-2024 | |
| Redhill Biopharma INC. | $27.22 | 2021 | |
| Meridian Bioscience INC. | $24.76 | 2023 | |
| Conmed Corporation | $17.75 | 2025 | Conmed Generators |
| Digestive Care, INC. | $16.56 | 2023 | Pertzye |
| Axonics, INC. | $13.34 | 2022 | |
| Gilead Sciences, INC. | $12.90 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Bailey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.